A Phase 4 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Wet Macular Degeneration, sponsored by Bayer. Completed at 41 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) .
To assess the safety of IVT administration of aflibercept with two different approaches of Treat and Extend dosing regimen in Japanese subjects with wAMD for up to 2 years.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
This study's enrollment of 288 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Aflibercept 2mg is intravitreally injected.
Mean Change From Baseline in BCVA at Week 52
Visual functions of the study eye (at every visit) and the fellow eye were assessed, according to the ETDRS protocol as described in detail in the operation manual. A higher score represents better functioning.
Time frame: Baseline and Week 52
Percentage of Participants Who Maintained Vision at Week 52
A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.
Time frame: Week 52
Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52
Time frame: Baseline and Week 52
Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52
Time frame: Baseline and week 52
Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52
A participant was classified as without fluid if "Evidence of new or persistent fluid" on OCT was "No".
Time frame: Week 52
Study was conducted in Japan between 19 December 2014 (first participant first visit) and 08 November 2017 (last participant last visit).
| Milestone | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure |
|---|---|---|---|
| Started | 124 | 123 | 8 |
| Treated | 124 | 123 | 7 |
| Randomized | 124 | 123 | 0 |
| Bcva post-randomization assessment | 123 | 123 | 0 |
| Completed | 108 | 104 | 0 |
| Not completed | 16 | 19 | 8 |
| Withdrew: Death | 2 | 1 | 0 |
| Withdrew: Progressive disease | 4 | 4 | 0 |
| Withdrew: Logistical difficulties | 1 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 3 | 0 |
| Withdrew: Physician decision | 2 | 1 | 0 |
| Withdrew: Adverse event | 4 | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 0 |
| Withdrew: Randomized failure | 0 | 0 | 8 |
| Withdrew: Required procedure failed | 0 | 1 | 0 |
Visual functions of the study eye (at every visit) and the fellow eye were assessed, according to the ETDRS protocol as described in detail in the operation manual. A higher score represents better functioning.
| letters | 2 Weeks Adjustment | 4 Weeks Adjustment |
|---|---|---|
| Mean Change From Baseline in BCVA at Week 52 | 9.0 ± 14.6 | 8.4 ± 13.4 |
A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.
| percentage of participants | 2 Weeks Adjustment | 4 Weeks Adjustment |
|---|---|---|
| Percentage of Participants Who Maintained Vision at Week 52 | 96.7 (93.6 to 99.9) | 95.9 (92.4 to 99.4) |
| percentage of participants | 2 Weeks Adjustment | 4 Weeks Adjustment |
|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52 | 32.5 (24.2 to 40.8) | 30.9 (22.7 to 39.1) |
| μm | 2 Weeks Adjustment | 4 Weeks Adjustment |
|---|---|---|
| Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52 | -134.4 (-162.2 to -106.6) | -126.1 (-147.1 to -105.1) |
A participant was classified as without fluid if "Evidence of new or persistent fluid" on OCT was "No".
| Percentage of participants | 2 Weeks Adjustment | 4 Weeks Adjustment |
|---|---|---|
| Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52 | 68.3 (60.1 to 76.5) | 69.1 (60.9 to 77.3) |
Collected over Up to 96 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 Weeks Adjustment | — | 19/124 (15.3%) | 49/124 (39.5%) |
| 4 Weeks Adjustment | — | 20/123 (16.3%) | 61/123 (49.6%) |
| Randomization Failure | — | 3/7 (42.9%) | 4/7 (57.1%) |
| Event | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/124 | 0/123 | 2/7 |
| Cholecystitis acuteHepatobiliary disorders | 0/124 | 0/123 | 1/7 |
| CataractEye disorders | 4/124 | 5/123 | 0/7 |
| CholelithiasisHepatobiliary disorders | 2/124 | 1/123 | 0/7 |
| Acute myocardial infarctionCardiac disorders | 0/124 | 1/123 | 0/7 |
| Angina pectorisCardiac disorders | 0/124 | 1/123 | 0/7 |
| Coronary artery stenosisCardiac disorders | 0/124 | 1/123 | 0/7 |
| TachycardiaCardiac disorders | 0/124 | 1/123 | 0/7 |
| Sinus node dysfunctionCardiac disorders | 0/124 | 1/123 | 0/7 |
| IleusGastrointestinal disorders | 0/124 | 1/123 | 0/7 |
| Event | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 26/124 | 20/123 | 0/7 |
| Atrial fibrillationCardiac disorders | 0/124 | 0/123 | 1/7 |
| ToothacheGastrointestinal disorders | 1/124 | 1/123 | 1/7 |
| Oedema peripheralGeneral disorders | 1/124 | 1/123 | 1/7 |
| Cholecystitis acuteHepatobiliary disorders | 0/124 | 0/123 | 1/7 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/124 | 1/123 | 1/7 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/124 | 0/123 | 1/7 |
| HypertensionVascular disorders | 1/124 | 4/123 | 1/7 |
| CataractEye disorders | 5/124 | 10/123 | 0/7 |
| Conjunctival haemorrhageEye disorders | 4/124 | 8/123 | 0/7 |
Safety analysis set (SAF): included all subjects who received any study drug
| Age, Continuous(years) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Mean | 73.0 ± 7.9 | 75.0 ± 8.1 | 80.3 ± 7.8 | 74.2 ± 8.1 |
| Sex: Female, Male(Participants) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Female | 36 | 32 | 1 | 69 |
| Male | 88 | 91 | 6 | 185 |
| Best-corrected visual acuity (BCVA)(letters) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Mean | 54.6 ± 13.1 | 55.3 ± 12.0 | 54.9 ± 17.9 | 55.0 ± 12.7 |
| Central Retinal Thickness(μm) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Mean | 386.5 ± 158.6 | 370.3 ± 120.0 | 371.6 ± 88.5 | 378.3 ± 139.4 |
| Choroidal neovascularization(Participants) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| No CNV | 0 | 1 | 0 | 1 |
| Classic CNV | 35 | 42 | 1 | 78 |
| Classic & Occult | 15 | 17 | 2 | 34 |
| Occult | 72 | 62 | 4 | 138 |
| Unknown | 2 | 1 | 0 | 3 |
| Typical age-related macular degeneration(Participants) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Missing | 2 | 0 | 0 | 2 |
| No | 46 | 48 | 2 | 96 |
| Yes | 76 | 75 | 5 | 156 |
| Polypoidal Choroidal Vasculopathy(Participants) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Missing | 2 | 0 | 0 | 2 |
| No | 76 | 79 | 5 | 160 |
| Yes | 46 | 44 | 2 | 92 |
| Retinal Angiomatous Proliferation(Participants) | 2 Weeks Adjustment | 4 Weeks Adjustment | Randomization Failure | Total |
|---|---|---|---|---|
| Missing | 2 | 0 | 0 | 2 |
| No | 118 | 114 | 6 | 238 |
| Yes | 4 | 9 | 1 | 14 |
Ran from Dec 2014 to primary completion in Dec 2016, 24 months.
Results were first posted in Mar 2018, 1 year 2 months after primary completion.
Of 12 phase 4 interventional studies under Wet Macular Degeneration, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 38. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept